Amgen
The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants
Inclusion Criteria: * Healthy male or female participants, 18 to 60 years of age. * First-generation Chinese ancestry (born in China, Hong Kong, Taiwan, or Macau with 2 Chinese parents and 4 Chinese grandparents) or first-generation Japanese ancestry (born in Japan with 2 Japanese parents and 4 Japanese grandparents). * Body mass index (BMI) 18.0 to 30.0 kg/m\^2 (inclusive) and body weight ≥40 kg. * In good general health based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations. * Female participants must not be pregnant or brea…
AMG 691 will be administered subcutaneously
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.